Overexpression and activation of tyrosine kinase Src has been linked to breast carcinogenesis and bone metastases. We conducted a phase II trial in patients with HER2-negative metastatic breast cancer receiving weekly paclitaxel and the SRC inhibitor dasatinib (120 mg daily). The primary end point was response according to Response Evaluation Criteria in Solid Tumors and secondary end points included progression-free survival (PFS) and overall survival (OS). We enrolled 40 patients, including 2 men, but the study was stopped early because of slow accrual. The overall response rate was 23%. The median PFS and OS was 5.2 (95% confidence interval [CI], 2.9-9.9) and 20.6 (95% CI, 12.9-25.2) months, respectively. Toxicities were as expected and included fatigue, neuropathy, and diarrhea. We were unable to find any predictive biomarker of treatment benefit. Background: Overexpression and activation of tyrosine kinase Src has been linked to breast carcinogenesis and bone metastases. We showed the feasibility of combining the SRC inhibitor dasatinib with weekly paclitaxel in patients with metastatic breast cancer (MBC) and herein report the subsequent phase II trial. Patients and Methods: Patients had received 2 chemotherapy regimens for measurable, HER2-negative MBC. Patients received paclitaxel and dasatinib (120 mg daily) and were assessed according to Response Evaluation Criteria in Solid Tumors for overall response rate (ORR), the primary end point. Secondary end points included progression-free survival (PFS) and overall survival (OS). A 30% ORR (n ¼ 55) was deemed worthy of further investigation. Exploratory biomarkers included N-telopeptide (NTX) and plasma vascular epidermal growth factor (VEGF) receptor 2 as predictors of clinical benefit. Results: From March 2010 to March 2014, 40 patients, including 2 men enrolled. The study was stopped early because of slow accrual. Overall, 32 patients (80%) had estrogen receptor-positive tumors and 23 (58%) had previously received taxanes. Of the 35 assessable patients, 1 (3%) had complete response and 7 (20%) partial response, resulting in an ORR of 23%. The median PFS and OS was 5.2 (95% confidence interval [CI], 2.9-9.9) and 20.6 (95% CI, 12.9-25.2) months, respectively. As expected, fatigue (75%), neuropathy (65%), and diarrhea (50%) were common side effects, but were generally low-grade. Median baseline NTX was similar in patients who had clinical benefit (8.2 nmol BCE) and no clinical benefit (10.9 nmol BCE). Similarly, median baseline VEGF levels were similar between the 2 groups; 93.0 pg/mL versus 83.0 pg/mL. Conclusion: This phase II study of dasatinib and paclitaxel was stopped early because of slow accrual but showed some clinical activity. Further study is not planned.
Introduction
Overexpression and activation of tyrosine kinase Src, a membrane-associated nonreceptor tyrosine kinase has been linked to breast carcinogenesis. [1] [2] [3] [4] SRC kinases enhance metastatic growth and survival of breast cells in the bone marrow microenvironment. 5, 6 In addition, Src kinases play a part in the activation of osteoclasts, contributing to the development of late-onset bone metastases. 5, 6 Osseous metastases are a common occurrence, affecting up to 70% of patients with metastatic breast cancer (MBC). 7, 8 Hence, it is hypothesized that inhibitors of Src might have a role in the treatment of MBC, and might be of particular interest in patients with bone metastases. To date, many breast cancer targeted therapies have focused on the estrogen receptor (ER), and HER2, although bone-modifying agents such as bisphosphonates, and receptor activator of nuclear factor k B ligand inhibitors have improved the outcome for patients with bone metastases irrespective of breast cancer phenotype. 9, 10 Because of its importance to many patients with breast cancer and the possible role in treating breast cancer bone metastases, we were particularly interested in targeting SRC as a therapeutic approach. Dasatinib is an adenosine triphosphate-competitive inhibitor, which inhibits several tyrosine kinases, including members of the SRC family. 11 This oral agent is approved by the Food and Drug
Administration for chronic myelogenous leukemia and has been studied in various solid tumors. 12 Preclinical studies have shown that dasatinib inhibits the growth of cells that express activated SRC, and has particular activity in triple-negative breast cancer (TNBC) that lacks expression of ER, progesterone receptor, and HER2. [13] [14] [15] Dasatinib has limited clinical activity as a single agent in breast cancer, but might have greater antitumor activity in 
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Phase II Paclitaxel and Dasatinib in Breast Cancer combination with other agents. 16 Preclinically, the combination of dasatinib and paclitaxel, a highly active cytotoxic agent with nonoverlapping toxicity profile, showed greater antitumor activity than either single agent. 17 We previously conducted a phase I study and showed that the combination of weekly paclitaxel (80 mg/m 2 )
and dasatinib (120 mg orally) was feasible. 18 In this article, we report the results of the subsequent phase II study of this combination in MBC.
Patients and Methods
Patients with HER2-negative locally advanced or MBC, irrespective of ER status were eligible. All patients were required to have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST), performance status of 0 or 1 (Eastern Cooperative Oncology Group scale), and normal organ function (hematologic, renal, and hepatic). 19 Up to 2 previous chemotherapy regimens for metastatic disease were permitted. Exclusion criteria included previous severe allergic reactions to paclitaxel, symptomatic central nervous system metastases, preexisting neuropathy (Grade >1), and uncontrolled gastrointestinal malabsorption syndromes. Because of the risk of fluid retention with dasatinib, patients with symptomatic pleural effusion were not permitted to participate. Patients were not permitted to take potent cytochrome P450 3A4 inhibitors or agents associated with QT prolongation. Women of childbearing potential were required to use adequate contraception. All patients were required to have a paraffin-embedded tissue block or unstained slides available for correlative biomarker research.
Study Design
This study was designed as a Ib-II open label trial and the results of the phase I study have been reported separately. 18 For the phase II trial paclitaxel (80 mg/m 2 ) was given intravenously over 1 hour on days 1, 8, and 15 of a 28 day cycle and dasatinib 120 mg was given orally in a single daily dose as recommended from the phase I portion. 18 Paclitaxel and dasatinib doses were adjusted for toxicity and treatment could be delayed for no more than 3 weeks due to toxicity. Treatment was continued until disease progression, unacceptable toxicity, or consent withdrawal. Because of the risk of hypocalcemia with dasatinib therapy, patients were not permitted to receive bone-targeting agents for the first 8 weeks of treatment. Patients were assessed every 4 weeks for adverse events and RECIST assessment was performed after the first 2 cycles of treatment and every 3 cycles thereafter. The primary end point was overall response rate (ORR), defined, according to RECIST criteria as the percentage of patients achieving either an objective complete response (CR) or a partial response (PR). 19 On the basis of previous single-agent response rates for paclitaxel, a 15% response rate was chosen for futility and 30% for the combination to be deemed worthy of further investigation. 20 The phase II portion of the study used a Simon 2-stage optimal design with type I and II errors set at 0.10: if responses were seen in ! 4 of 23 (17.4%) patients, enrollment was extended to a total of 55 patients. Using this design if 12 of 55 patients had an ORR, then the study would be considered to have a positive result and this regimen would be considered worthy of further testing. On the basis of these hypotheses, the probability of early termination was 54% if the true ORR was 15%. Secondary end points included: clinical benefit (the sum of the percentage of patients who achieved CR, PR, and stable disease [SD] for > 6 months), time to tumor progression (TTP), progression-free survival (PFS), and safety and tolerability of the combination. We also explored the activity of the combination in patients with bone metastases. Exploratory tumor biomarkers included collagen type IV (or N-telopeptide [NTX]), plasma vascular epidermal growth factor (VEGF) receptor 2, and circulating tumor cells 
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Results
From March 2010 to March 2014, 40 patients, including 2 men, were enrolled (Table 1) . In total 32 patients (80%) had ERpositive, HER2-negative tumors and 8 (20%) had TNBC. The Phase II Paclitaxel and Dasatinib in Breast Cancer most common site of metastases was bone (60%) and most patients (73%) had visceral disease. Patients were generally quite heavily pretreated: 55% had received 1 or more lines of hormone therapy and 65% had received at least 1 line of chemotherapy for advanced disease. Of note, 23 (58%) had previously been treated with a taxane, either for early (n ¼ 20) or advanced (n ¼ 3) breast cancer.
Response
Responses were seen in ! 4 of 23 patients (17.4%) and enrollment was extended per protocol to stage 2. However, because of the slow accrual over a 4-year period, the study was stopped prematurely. Of the final 40 patients, 5 (13%) discontinued treatment before the end of cycle 2. Two of these had hypersensitivity reactions to paclitaxel and 3 discontinued because of unacceptable toxicity, including nausea and diarrhea. Therefore, 35 patients (88%) were evaluable for response per protocol (Figure 1 ). Of these, 1 patient (3%) had a CR and 7 patients (20%) had a PR, resulting in an ORR of 23%. In total, 3 of 8 patients with disease response had received previous paclitaxel. The patient who achieved a CR had TNBC and all of the patients who had a PR had ER-positive breast cancer. Overall, the maximum diameter of measurable lesions decreased from baseline in 24 patients (69%; Figure 2 ).
Per protocol, PR was confirmed using repeat computed tomography imaging in 6 of 7 patients (86%). One patient with PR discontinued treatment because of excessive toxicity and 1 patient with CR withdrew consent, before response confirmation. The 8 patients who had CR/PR continued treatment for a median of 10.4 months (range, 2.4-26.1 months), including 3 patients who received treatment for > 1 year. The best response to treatment was stable disease in 14 patients (40%); of whom 7 (50%) had stable disease for ! 6 months. Therefore, the clinical benefit rate (per protocol) was 43% (15 of 35). Of these patients, 11 of 15 (73%) had bone metastases, 6 of 15 (40%) had received previous taxanes, and only 1 patient (3%) had TNBC.
Bone Metastases
In total, 27 patients (68%) had bone metastases, of whom 24 (89%) were assessable for response. Of these, 11 (46%) had clinical benefit and 13 (54%) did not. The ORR was 15% (4 of 27, all PR) and 7 of 27 (26%) had SD. However, 3 of 27 patients with bone metastases continued treatment for ! 18 months.
Progression-Free Survival and Overall Survival
Of the 40 enrolled patients, treatment was discontinued in 10 patients (25%) because of excessive toxicity, in 26 (65%) for disease progression, and 4 patients (10%) withdrew consent. All patients have now discontinued study drugs because of tumor progression in 38 of 40 patients (95%). Overall, 30 patients (75%) have died. The median PFS for all patients was 5.2 (95% confidence interval [CI], 2.9-9.9) months ( Figure 3A ) and the median overall survival OS was 20.6 (95% CI, 12.9-25.2) months ( Figure 3B ). Median TTP was 5.84 (range, 0-25.7) months. Median TTP in patients with TNBC was 1.8 months compared with 6.8 months in those with ER-positive disease (P ¼ .052).
Toxicities
In total, 8 patients (20%) required a dose reduction to dasatinib 100 mg; mostly because of fatigue and diarrhea, which subsequently improved. The most common toxicities were hematological and similar to those reported in the previous phase I study (Tables 2 and 3) . Two patients developed pleural effusions, which were at least possibly related to dasatinib. One patient developed a Grade 2 pleural effusion at the first tumor assessment and discontinued treatment for disease progression. Another patient with stable disease had a worsening of a preexisting small pleural effusion after 7 months of therapy. As expected, fatigue (75%), neuropathy (65%), and diarrhea (50%) were common side effects, but were generally Grade 1 (Table 2) . Grade 2 fatigue, neuropathy, and diarrhea occurred in only 10%, 2.5%, and 15% of patients, respectively, and no patients had Grade ! 3 events. 
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Overall, 19 patients (48%) had some skin toxicity, which included acneiform rash and hand-foot syndrome, although events were Grade 1 in almost all (17 of 19) patients. Similarly, peripheral edema occurred in 13 patients (33%), but was Grade 1 in almost all (11 of 13) patients and was mostly unrelated to dasatinib. Prolonged QTc interval occurred in 4 patients (10%), 
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although it was asymptomatic and did not result in any significant arrhythmia.
Biomarkers
Among patients who had clinical benefit per protocol (n ¼ 15), baseline NTX, VEGF, and CTCs were available in 14 (93%), 13 (87%), and 14 (93%) patients, respectively (Figure 1 ). Among patients who had no clinical benefit per protocol (n ¼ 20), baseline NTX, VEGF, and CTCs were available in 19 (95%), 19 (95%), and 20 (100%) patients, respectively ( Figure 1 ). As shown in Figure 4A , median baseline NTX was similar in patients who had clinical benefit (8.2 nmol BCE) and no clinical benefit (10.9 nmol BCE). Similarly, median baseline VEGF and CTC levels were similar between the 2 groups; 93.0 pg/mL versus 83.0 pg/mL ( Figure 4B ) and 3.5 versus 3.0 ( Figure 4C ). respectively. After 2 cycles of treatment, these biomarkers did not correlate with clinical benefit.
Discussion
In this phase II study of dasatinib and paclitaxel the ORR was 23% (8 of 35), which was below the a priori 30% threshold deemed worthy of further study. However, definitive conclusions are limited because the study closed after 4 years because of slow accrual. Disease control was seen, including in taxane-pretreated patients and the toxicities were similar to our previous phase I study; diarrhea (50%), neuropathy (65%), and fatigue (75%) were common. 18 Although individual toxicities were generally low-grade, it is likely that these had an effect on the investigators' decisions to recommend the trial to potential patients. Ultimately, this meant that accrual to a follow-up phase III study would likely have been virtually impossible. Preclinical studies predicted that dasatinib, a potent inhibitor of Src and other tyrosine kinases, would have significant activity in breast cancer. 3, 4 However, single-agent dasatinib (100 mg once daily or 70 mg twice daily) appears to have limited activity in unselected MBC. 16 Therefore, supported by preclinical work, several studies, like ours, have examined dasatinib with cytotoxic chemotherapy. 21, 22 In our previous phase I study of the same combination a 31% (4 of 13) response rate was seen. 18 Similarly, in a phase I trial of dasatinib and capecitabine the response rate was 24% (6 of 25 patients). 21 The response rate in the current study (23%) was somewhat disappointing, but relatively similar to that seen in the previous (smaller) phase I trial (31%). Collectively, available data from phase I/II trials suggest limited activity for dasatinib with chemotherapy in unselected patients with MBC. We had hoped to identify a cohort of patients who would derive relatively greater benefit from dasatinib using clinical or biomarker criteria. Because Src activates osteoclasts and is important for the development of osseous metastases, we hypothesized that dasatinib would have greatest benefit in patients with breast cancer bone metastases. [3] [4] [5] [6] Despite this rationale, the ORR for this subgroup was only 15% in our study. However, 3 of 27 patients with bone metastases continued treatment for !18 months, which is noteworthy because of the limitation in assessing response in bone using RECIST. The concept that dasatinib could be useful in targeting breast cancer bone metastases was previously investigated in a phase I/II study in combination with zoledronic acid. 23 Although a response rate of 23% (5 of 22 patients) was seen, the median time to treatment failure was only 2.7 months in that study. 23 The observation that 7 of 8 patients who had disease response according to RECIST had ER-positive breast cancer is also interesting, but also conversely suggests very limited activity in TNBC. Despite a preclinical rationale for dasatinib in TNBC, median TTP was only 1.8 months in these patients. 14, 15 These results are overall disappointing and argue that dasatinib does not have a role in unselected patients with breast cancer bone metastases. Because this was a single-arm study there can be no conclusions about the relative effect of either paclitaxel or dasatinib monotherapy on disease control. However, the fact that 3 of 8 patients with disease response had received previous paclitaxel, suggests at least some activity for dasatinib. However, we cannot exclude the possibility that these patients had particularly indolent disease, which was likely to respond to many different treatments (such as a taxane rechallenge). Because Src is important for the development of endocrine resistance, an alternative approach is the possible role of Src inhibitors in combination with endocrine therapy. 24 Although letrozole in combination with dasatinib has shown encouraging PFS in a phase II study of postmenopausal women with ER-positive HER2-negative MBC, the overall results were also somewhat disappointing. 25 Because only a subset of patients derived clinical benefit in the current study, the identification of biomarkers was of major interest. Despite a high rate of compliance with baseline serum biomarker acquisition, we were unable to show any correlation between clinical benefit and predetermined biomarkers, NTX, VEGF, or CTCs. Other studies have examined a series of biomarkers to predict dasatinib benefit with limited success. 21, 26 Pusztai and colleagues examined tumor gene expression using 3 different predictive signatures, modified from cell line studies. 26 Despite the large sample size (93 biopsies from 97 patients) and rigorous techniques, they were unable to identify tissue predictors of dasatinib benefit. In a phase I study in breast cancer, dasatinib (100 mg daily) and capecitabine led to a decrease in VEGF-A by a median of 49.5% at 3 weeks and a corresponding increase in NTX by 22.9%, suggesting antiangiogenic as well as Src inhibition. 21 In contrast, dasatinib 150 mg combined with 5-fluorouracail, oxaliplatin, and cetuximab failed to show any significant evidence of Src inhibition in a phase Ib/II study in metastatic colorectal cancer. 27 Specifically, there was no change in tumor expression of phospho-Src after 3 weeks of combination treatment in patients with paired tumor samples taken from liver metastases. Collectively, these results suggest that although dasatinib with chemotherapy is associated with a decrease in serum biomarkers of angiogenesis and Src, there does not appear to be demonstrable Src inhibition within metastases, thereby limiting clinical utility of this agent. Overall, this phase II study showed some clinical activity for the combination of dasatinib and paclitaxel in an unselected cohort of patients with MBC, but the slow accrual and cumulative toxicities mean that a confirmatory phase III study is not planned. It is hoped that biomarkers might allow the development of more potent, highly specific Src inhibitors in carefully selected patients with breast cancer in the future.
Clinical Practice Points
Although there was a strong biological rationale for combining the SRC inhibitor dasatinib with paclitaxel in MBC, this
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